Daniel Crowley

Dan earned his MBA at Cornell where he was an Angear Merit Scholar, and a Master's diploma in strategy and innovation at Oxford. He holds a BA and MSc from the school of Engineering and Systems Sciences at Trinity College Dublin. 

Dan is an investor and entrepreneur in life sciences and related areas. He has had a direct role in the formation and financing of several dozen companies in sensors, advanced materials, energy, semiconductors, bioinformatics, generative AI, genomics, and single cell technologies.

​

Dan is currently co-founder and CEO of RemedyBio, a biotech pioneering a new way to discover safe and effective therapies against cancer and immune disease, by creating a technology for analysing and searching the function of millions of living cells at time.

​

Previously Dan co-founded  Genomics Medicine Ireland (GMI), a venture backed company discovering novel targets from large scale population genomics. Dan led the company from founding to its acquisition in 2018 by Genuity Sciences.

​

Dan served for almost a decade as Venture Partner at ARCH Venture Partners, and as a Director at ARCH Europe. Prior to ARCH he was a Director with NDRC, an leading early-stage investor in Dublin, Ireland, where we has the founding director of one of Europe's first science venture accelerators.

A member of Class 16, Dan served his fellowship at ARCH Ventures and NDRC ,under the mentorship of Paul Thurk (Fellows Class 6) of ARCH Venture Partners.